XmAb541

BIOLOGICAL2 trials

Sponsors

Xencor, Inc.

Conditions

Endometrial CancerGerm Cell TumorOvarian CancerOvarian Germ Cell TumorTesticular Germ Cell Tumor

Phase 1

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

RecruitingNCT06276491

Xencor, Inc.Endometrial Cancer, Germ Cell Tumor, Ovarian Cancer +2

Start: 2024-04-04End: 2028-12-01Target: 282Updated: 2026-08-25

Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors

RecruitingNCT07593092

Xencor, Inc.Ovarian Cancer

Start: 2026-06-30End: 2028-12-01Target: 90Updated: 2026-08-13

Related Papers

A phase 1, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (claudin-6 x CD3) T-cell engaging bispecific antibody in subjects with germ cell tumors and other advanced solid tumors.

Journal of Clinical Oncology2025-02-10